Form 4: NeoGenomics EVP Olivo Reports Equity Transactions
Insider Transaction Report
Alicia C. Olivo, EVP, GC & Business Development at NeoGenomics Inc., reported the vesting of restricted stock units and related tax-driven share dispositions, alongside various stock option and performance unit holdings.
Summary
- Alicia C. Olivo, EVP, GC & Business Development, reported transactions on January 13, 2026, related to her equity holdings in NeoGenomics Inc.
- Acquired 59,382 shares of common stock due to the vesting of restricted stock units.
- Disposed of 15,145 shares of common stock to satisfy tax withholding obligations related to the RSU vesting.
- Following these transactions, Ms. Olivo beneficially owns 75,320 shares of common stock directly.
- The filing details various outstanding derivative securities, including stock options and performance stock units, with different grant dates, vesting schedules, and expiration dates.
- Notable grants include 107,450 premium-price stock options and 63,238 restricted stock units granted on February 21, 2025, both vesting ratably over three years.
Sentiment
Score: 6
Explanation: The filing reflects routine executive compensation activities, including the vesting of equity awards and associated tax dispositions. It indicates ongoing executive alignment with company performance through various equity instruments, which is generally positive for governance, but does not present new material financial information.
Positives
- Vesting of 59,382 restricted stock units, converting into common stock, indicates compensation realization for the executive.
- Continued holding of significant derivative securities (stock options, restricted stock units, performance stock units) aligns management's interests with shareholder value.
Negatives
- Disposition of 15,145 shares of common stock to cover tax withholding obligations, which reduces direct share ownership.
Future Outlook
NA
Industry Context
This Form 4 filing is a standard disclosure of insider equity transactions and does not provide broader industry context or trends. It reflects the individual compensation activities of a senior executive within the company.
Stakeholder Impact
- Shareholders: The vesting and disposition of shares by an executive are a normal part of compensation, aligning executive interests with shareholder value. Tax-related sales are common and expected.
- Employees: Reflects the company's executive compensation practices, which may influence broader employee compensation strategies.
Next Steps
- Continued vesting of various stock options, restricted stock units, and performance stock units according to their respective schedules.
- Achievement of share growth and revenue growth goals for performance stock units to maximize vesting.
Key Dates
| Date | Description |
|---|---|
| 09/30/2019 | Grant date for 1,394 stock options to Ms. Olivo, vesting ratably over four years. |
| 05/01/2020 | Grant date for 1,024 stock options to Ms. Olivo, vesting ratably over four years. |
| 05/01/2021 | Grant date for 516 stock options to Ms. Olivo, vesting ratably over four years. |
| 08/01/2021 | Grant date for 1,117 stock options to Ms. Olivo, vesting ratably over four years. |
| 05/01/2022 | Grant date for 22,222 stock options to Ms. Olivo, vesting ratably over four years. |
| 09/01/2022 | Grant date for 55,332 stock options to Ms. Olivo, vesting ratably over four years. |
| 05/11/2023 | Grant date for 36,508 stock options, 19,508 restricted stock units, and 19,508 performance stock units to Ms. Olivo. |
| 02/23/2024 | Grant date for 42,344 stock options, 25,330 performance stock units, and 25,329 restricted stock units to Ms. Olivo. |
| 02/20/2025 | Closing price used to calculate the premium exercise price for stock options granted on February 21, 2025. |
| 02/21/2025 | Grant date for 107,450 stock options and 63,238 restricted stock units to Ms. Olivo. |
| 01/13/2026 | Date of earliest transaction reported, involving RSU vesting and tax-related share disposition. |
| 01/15/2026 | Signature date of the reporting person on the Form 4. |
| 05/11/2026 | Expiration date for 19,508 performance stock units granted on May 11, 2023. |
| 09/30/2026 | Expiration date for 1,046 stock options granted on September 30, 2019. |
| 05/01/2027 | Expiration date for 1,024 stock options granted on May 1, 2020. |
| 02/23/2027 | Expiration date for 25,330 performance stock units granted on February 23, 2024. |
| 05/01/2028 | Expiration date for 516 stock options granted on May 1, 2021. |
| 08/01/2028 | Expiration date for 1,117 stock options granted on August 1, 2021. |
| 05/01/2029 | Expiration date for 22,222 stock options granted on May 1, 2022. |
| 09/01/2029 | Expiration date for 46,355 stock options granted on September 1, 2022. |
| 05/11/2030 | Expiration date for 36,508 stock options granted on May 11, 2023. |
| 02/23/2034 | Expiration date for 42,344 stock options granted on February 23, 2024. |
| 02/21/2035 | Expiration date for 107,450 stock options granted on February 21, 2025. |
Recommendation
holdThis Form 4 filing details routine executive compensation events, specifically the vesting of restricted stock units and the subsequent sale of shares to cover tax obligations. While it confirms an executive's continued equity holdings and alignment with company performance, it does not introduce new material information that would fundamentally alter the investment thesis for NeoGenomics. Therefore, a 'hold' recommendation is appropriate as the filing does not provide a catalyst for a change in investment strategy.
Keywords
NeoGenomics, NEO, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Performance Stock Units, Executive Compensation, Alicia C. Olivo, Equity Transactions
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.